Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.

Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J.

Leukemia. 2006 Jul;20(7):1288-90. Epub 2006 May 11. No abstract available.

PMID:
16688228
2.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G.

Blood. 2003 Sep 1;102(5):1588-94. Epub 2003 May 1.

3.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.

Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, et al.

Stem Cells. 1995 Aug;13 Suppl 2:132-9.

PMID:
8520502
4.

Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.

Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.

5.

High-dose chemotherapy in multiple myeloma.

Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R.

Leukemia. 1997 Dec;11 Suppl 5:S27-31. Review.

PMID:
9436935
6.

Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.

Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, Hwang SM, Kim M, Kim HK, Kim I, Yoon SS, Park S, Kim BK, Lee JH, Lee DS; Korea Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2011 Jun;17(6):810-20. doi: 10.1016/j.bbmt.2011.01.002. Epub 2011 Jan 8.

7.

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.

Bone Marrow Transplant. 1999 Sep;24(5):497-503.

9.

An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.

Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC, Premalatha P, Lao ZT, Wee N, Choo C, Wee HC, Su S, Lee YS, Lee LH, Hwang W, Goh YT.

Am J Hematol. 2010 Oct;85(10):752-6. doi: 10.1002/ajh.21812.

10.

[The importance of autologous transplantation in multiple myeloma].

Pour L, Hájek R, Adam Z, Krejcí M, Vorlícek J.

Vnitr Lek. 2009 Sep;55(9):767-72. Review. Czech.

PMID:
19785373
11.

High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK.

Expert Rev Anticancer Ther. 2006 Mar;6(3):343-60. Review.

PMID:
16503852
12.

Intensive therapy in multiple myeloma.

Harousseau JL.

Pathol Biol (Paris). 1999 Feb;47(2):203-9. Review.

PMID:
10192890
13.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network.

Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.

14.

Tandem autologous stem cell transplantation in multiple myeloma after high-dose chemotherapy with two separate collections: single institution experience.

Ladicka M, Ballova V, Drgona L, Vranovsky A, Lakota J.

Neoplasma. 2012;59(5):551-8. doi: 10.4149/neo_2012_071.

PMID:
22668021
15.

The role of autologous stem cell transplantation in the management of multiple myeloma.

Fermand JP, Brechignac S.

Pathol Biol (Paris). 1999 Feb;47(2):199-202. Review.

PMID:
10192889
16.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party.

N Engl J Med. 2003 May 8;348(19):1875-83.

17.

Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.

Vesole DH, Simic A, Lazarus HM.

Bone Marrow Transplant. 2001 Oct;28(8):725-35. Review.

18.

Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.

Björkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, Auzanneau G, Bladé J, Brunet S, Carlson K, et al.

Stem Cells. 1995 Aug;13 Suppl 2:140-6.

PMID:
8520503
19.

Single versus double autologous stem-cell transplantation for multiple myeloma.

Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome.

N Engl J Med. 2003 Dec 25;349(26):2495-502. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628.

20.

Hematopoietic stem cell transplants for multiple myeloma.

Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B.

Leuk Lymphoma. 1996 Jun;22(1-2):25-36. Review.

PMID:
8724525

Supplemental Content

Support Center